Hemab Therapeutics Holdings COAG
NASDAQ COAG
$40.86 +1.48 (+3.76%)
At close: Nov 13, 2026 · 4:00 PM EST

Hemab Therapeutics Holdings (COAG) Operating Leases (2024 - 2026)

Updated

Analysis

Hemab Therapeutics Holdings (COAG) Operating Leases (2024 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,359.75 Bn 1,333.37 Bn 20.46 Bn
2 Johnson & Johnson 688.76 Bn 608.62 Bn 17.30 Bn
3 AbbVie 521.69 Bn 489.75 Bn 13.12 Bn
4 Merck 364.31 Bn 327.31 Bn 13.19 Bn
5 Novartis Ag 306.35 Bn 279.93 Bn -
6 Astrazeneca 285.96 Bn 259.56 Bn 13.26 Bn
7 Amgen 251.88 Bn 203.53 Bn 7.58 Bn
8 Gilead Sciences 208.59 Bn 183.61 Bn 6.73 Bn
9 Pfizer 164.73 Bn 112.38 Bn 12.56 Bn
10 Hemab Therapeutics Holdings 1.91 Bn 672.70 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 503,000.00
Jun 30, 2026 566,000.00
Mar 31, 2026 519,000.00
Dec 31, 2025 573,000.00
Dec 31, 2024 1.06 Mn
API Access

Hemab Therapeutics Holdings Operating Leases API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=operating-leases&ticker=COAG&period=max&api_key=YOUR_API_KEY